immun-ops2020, Author at Immuneering Corporation

Atebimetinib (IMM-1-104) + Modified Gemcitabine/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results

Presented as an Encore Presentation at the PanCAN Scientific Summit on September 28th, 2025.

Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year

Presented at the 7th Annual RAS-Targeted Drug Development Summit in Boston on September 17th, 2025.

A Slow and Steady Approach to Pancreatic Cancer Therapy

Changing the Ways We Treat Cancer

A Slow And Steady Approach To Cancer Fighting

The MEK effect on cancer — a slow and steady approach to drug resistance

Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer

Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer

Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans

1 2 3 … 10 Next